Hematology Malignancy Innovations in Clinical Trials

UH Seidman Cancer Center - Innovations in Clinical Trials - publication cover

Current Issue:

May 2017


Past Issues:

October 2016


August 2015

  • JAN1A14: VMP +/- Daratumumab for untreated myeloma patients.
  • S1211: Elotuzumab and Bortezomib, Dexamethasone and Lenalidomide for newly diagnosed high-risk myeloma patients.
  • CASE4A13: Ixazomib (MLN9708) plus Panobinostat and Dexamethasone for relapsed myeloma
  • CASE1A09: Very low dose continuous azacytidine plus lenalidomide and dexamethasone for relapsed multiple myeloma.
  • E3A06: Lenalidomide for patients with high-risk smoldering myeloma
  • MLNM2A13: Ixazomib, lenalidomide and dexamethasone for newly diagnosed multiple myeloma
  • MLNM1A15: Ixazomib maintenance after induction therapy for patients ineligible for autologous transplantation

December 2014

  • MESO 1Z12: MSC Expanded Umbilical Cord Blood Transplant
  • CTN 1101: Umbilical Cord Blood vs. Haploidentical Transplants
  • BELL 1Z12: Haploidentical SCT with Genetically Modified T Cells to Stop GVHD
  • UNMC 1413: Lenalidomide Maintenance After Autologous SCT
  • CASE 9Z13: Targeted Marrow Irradiation in Reduced Intensity Stem Cell Transplant
  • CCASE 12Z13: Allogeneic Transplant for Patients with Sickle Cell Anemia
  • CASE 5913: Curcumin and Vitamin D for Patients with Early-Stage CLL Or SLL
  • PRE 1413: Rituximab vs. Obinotuzumab for Patients with Low-Burden, Advanced-Stage Follicular Lymphoma

April 2014

  • Treatment of High Risk Smoldering Myeloma
  • BCL2 Inhibition for High Risk Relapsed CLL
  • Lenalidomide plus R-CHOP for DLBCL
  • Methoxyamine and Temozolomide in Patients with Advanced Solid Tumors
  • Vaccine Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
  • Treatment of Renal Tumors in Poor Surgical Candidates

December 2013

  • Brentuximab Plus Bendamustine For Hodgkin Lymphoma In First Relapse
  • Oral Azacytidine For Myeloid Malignancies
  • Ex Vivo Umbilical Cord Blood Expansion With Human Mesenchymal Stem Cells (MSCs)
  • Differentiation Therapy For Acute Myeloid Leukemia